📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. (2017)

First Author: Jani M

Attributed to: Maximising Therapeutic Utility for Rheumatoid Arthritis using genetic and genomic tissue responses to stratify medicines. funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1136/annrheumdis-2015-208849

PubMed Identifier: 27245864

Publication URI: http://europepmc.org/abstract/MED/27245864

Type: Journal Article/Review

Volume: 76

Parent Publication: Annals of the rheumatic diseases

Issue: 1

ISSN: 0003-4967